Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 17Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, Follicular 1Leukemia 1IDH1 Mutation Myeloid Neoplasms 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1AML 1

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × ivosidenib × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡